Jaap Verweij
862 works · 70,681 citations · h-index 115
Top works
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
- Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
- Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
- Individual patient data analysis to assess modifications to the RECIST criteria
- RECIST revisited: A review of validation studies on tumour assessment
- Lessons learned from independent central review
- Cremophor EL
- Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
- KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
- Topoisomerase I inhibitors: topotecan and irenotecan
- Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
- Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
- Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
- Soft tissue sarcomas of adults: state of the translational science.
- New guidelines to evaluate the response to treatment in solid tumors
- Capecitabine, an Oral Fluoropyrimidine Carbamate With Substantial Activity in Advanced Colorectal Cancer: Results of a Randomized Phase II Study